Chancery Tosses Vividion IP Suit Over $2B Bayer Deal

By Jarek Rutz ( January 15, 2026, 6:27 PM EST) -- The Delaware Chancery Court on Thursday dismissed a biotech investor's suit accusing the co-founder of Vividion Therapeutics Inc. and others of diverting valuable intellectual property ahead of the company's $2 billion sale to Bayer Corp., finding the alleged misconduct could not have affected the merger price or process under Delaware law....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login